The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Kovalenko A.P.

Kirov Military Medical Academy, St. Petersburg, Russia

Misikov V.K.

Vladimirsky Regional Research Clinical Institute, Moscow, Russia

Iskra D.A.

Kirov Military Medical Academy, Saint-Petersburg, Russia

Koshkarev M.A.

Medical-military academy n.a. S.M. Kirov, Saint-Petersburg, Russia

Sinelnikov K.A.

Pokrovskaya City Hospital, St. Petersburg, Russia

Tardue scales in the diagnostic of spasticity

Authors:

Kovalenko A.P., Misikov V.K., Iskra D.A., Koshkarev M.A., Sinelnikov K.A.

More about the authors

Read: 11350 times


To cite this article:

Kovalenko AP, Misikov VK, Iskra DA, Koshkarev MA, Sinelnikov KA. Tardue scales in the diagnostic of spasticity. S.S. Korsakov Journal of Neurology and Psychiatry. 2019;119(9):83‑90. (In Russ.)
https://doi.org/10.17116/jnevro201911909183

Recommended articles:
Approaches to medi­cal reha­bilitation of patients with post-stroke hemianopsia. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(8-2):20-25
Arti­ficial inte­lligence in comprehensive reha­bilitation of people with disa­bilities. (Literature review). Problems of Balneology, Physiotherapy and Exercise Therapy. 2025;(3):54-61
Burnout syndrome: prevention, treatment and reha­bilitation. Rege­nerative Biotechnologies, Preventive, Digi­tal and Predictive Medi­cine. 2025;(3):61-68
The exoskeleton of the hand in modern habi­litation and reha­bilitation (analytical review). Russian Journal of Operative Surgery and Clinical Anatomy. 2025;(3):53-61

References:

  1. Bhadra N. Neuroprostheses for spasticity control. In: Kilgore K, editor. Implantable neuroprostheses for restoring function. Cambridge: Elsevier. 2015.
  2. Ertzgaard P, Anhammer M, Forsmark A. Regional disparities in botulinum toxin A (BoNT-A) therapy for spasticity in Sweden: budgetary consequences of closing the estimated treatment gap. Acta Neurol Scand. 2017;135(3):366-372. https://doi.org/10.1111/ane.12610
  3. Zorowitz R, Gillard P, Brainin M. Poststroke spasticity: sequelae and burden on stroke survivors and caregivers. Neurology. 2013;80:45-52. https://doi.org/10.1212/WNL.0b013e3182764c86
  4. Maynard F, Karunas R., Waring W. Epidemiology of spasticity following traumatic spinal cord injury. Arch Phys Med Rehabil. 1990;71(8):566-569.
  5. Rizzo M, Hadjimichael O, Preiningerova J, Vollmer T. Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler. 2004;10(5):589-595. https://doi.org/10.1191/1352458504ms1085oa
  6. Iskra DA, Kovalenko AP, Koshkarev MA, Dyskin DE. Spasticity: from pathophysiology to treatment. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(10):108-114. (In Russ.) https://doi.org/10.17116/jnevro2018118101108
  7. Spasticity: diagnosis and management. Editor, Allison Brashear; associate editor, Elie Elovic. Second edition, Demos Medical Publishing. 2016;139. ISBN 978-1-62070-072-3 — ISBN 978-1-61705-242-2 (e-book).
  8. Kovalenko AP, Kamaeva OV, Misikov VK, Poleshchuk YuR, Koshkarev MA. Scales and tests in the rehabilitation and treatment of patients with spasticity of the lower limbs. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(5):120-128. (In Russ.) https://doi.org/10.17116/jnevro201811851120
  9. Gracies JM, Bayle N, Vinti M, Alkandari S, Vu P, Loche CM, Colas C. Five-step clinical assessment in spastic paresis. Eur J Phis Rehabil. 2010;46(3):411-421. PMID: 20927007.
  10. Boyd RN, Graham HK. Objectives measurement of clinical findings in the use of botulinum toxin type A for the management of children with cerebral palsy. Eur J of Neur. 1999;6:23-25. https://doi.org/10.1111/j.1468-1331.1999.tb00031.x
  11. Mackey AH, Walt SE, Lobb G, Stott NS. Intraobserver reliability of the modified Tardieu scale in the upper limb of children with hemiplegia. Dev Med Child Neurol. 2004;46(4):267-272. PMID: 15077704.
  12. Gracies JM, Marosszeky JE, Renton R, Sandanam J, Gandevia SC, Burke D. Short-term effects of dynamic lycra splints on upper limb in hemiplegic patients. Arch Phys Med Rehabil. 2000;81(12):1547-1555. PMID: 11128888. https://doi.org/10.1053/apmr.2000.16346
  13. Mikhailenko AA. Clinical neurology (semiotics and topical diagnostics). Textbook. 2nd, rev. and extra. SPb.: «Publishing house FOLIANT»; 2012. (In Russ.)
  14. Kovalenko AP, Misikov VK. Botulinum toxin treatment of patients with brain damage coused lower limb spasticity. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2018;118(9):28-34. (In Russ.) https://doi.org/10.17116/jnevro201811809128
  15. Delgado MR, Tilton A, Russman B, Benavides O, Bonikowski M, Carranza J, Dabrowski E, Dursun N, Gormley M, Jozwiak M, Matthews D, Maciag-Tymecka I, Unlu E, Pham E, Tse A, Picaut P. AbobotulinumtoxinA for Equinus Foot Deformity in Cerebral Palsy: A Randomized Controlled Trial. Pediatrics. 2016;137(2):e20152830.
  16. Khat’kova SE, Akulov MA, Orlova OR, Usachev DYu, Orlova AS, Krylova LV. Botulinum toxin treatment of lower extremity spasticity. Nervno-mishechnie bolezni. 2017;7:27-35. (In Russ.) https://doi.org/10.17650/2222-8721-2017-7-3-21-35
  17. Gracies JM, Esquenazi A, Brashear A, Banach M, Kocer S, Jech R, Khatkova S, Benetin J, Vecchio M, McAllister P, Ilkowski J, Ochudlo S, Catus F, Grandoulier AS, Vilain C, Picaut P; International AbobotulinumtoxinA Adult Lower Limb. Spasticity Study Group. Efficacy and safety of abobotulinumtoxin A in spastic lower limb: Randomized trial and extension. Neurology. 2017;89(22):2245-2253. https://doi.org/10.1212/WNL.0000000000004687
  18. Gracies JM, O’dell M, Vecchio M, Hedera P, Kocer S, Rudzinska-Bar M, Rubin B, Timerbaeva SL, Lusakowska A, Boyer FOC, Grandoulier AS, Vilain C, Picaut F. Effects of Repeated Abobotulinumtoxina Injections in Upper Limb Spasticity Muscle Nerve. 2017;000:000-000. https://doi.org/10.1002/mus.25721
  19. Field M, Splevins A, Picaut F, Van der Schans M, Langenberg J, Noort D, Foster K. AbobotulinumtoxinA (Dysport), OnabotulinumtoxinA (Botox), and IncobotulinumtoxinA (Xeomin) Neurotoxin Content and Potential Implications for Duration of Response in Patients. Toxins. 2018;10:535. https://doi.org/10.3390/toxins10120535

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.